(Q44291997)

1 December 2017

title

Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary (English)

1 reference

1 December 2017

Davidson NG

1

1 reference

1 December 2017

Khanna S

series ordinal

2

1 reference

1 December 2017

Kirwan PH

series ordinal

3

1 reference

1 December 2017

Bircumshaw D

series ordinal

4

1 reference

1 December 2017

publication date

1 January 1991

1 reference

1 December 2017

1 reference

1 December 2017

volume

3

1 reference

1 December 2017

issue

1

1 reference

1 December 2017

page(s)

32-36

1 reference

CA125 as a serum marker for poor prognosis in ovarian malignancies

1 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

Reactivity of a monoclonal antibody with human ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

Treatment of stages II, III and IV primary surface epithelial ovarian cancers by maximum bulk tumour reduction and combined chemotherapy with cyclophosphamide, doxorubicin and cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

CA-125 monitoring during chemotherapy for ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

CA 125 and survival in ovarian cancer: preliminary communication

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens

1 reference

https://api.crossref.org/works/10.1016%2FS0936-6555%2805%2981038-6

7 January 2021

10.1016/S0936-6555(05)81038-6

Identifiers

DOI

1 reference

1 December 2017

1 reference